Funder: METAvivor
Due Dates: March 12, 2025 (Letter of Intent) | August 20, 2025 (Internal submission) | December 30, 2025 (Final submission)
Funding Amounts: Up to $200,000 total over two years; includes direct costs, up to $3,000 for travel, and up to 5% indirect costs.
Summary: Supports early-career researchers conducting innovative studies to advance treatment and understanding of metastatic breast cancer.
Key Information: Only research focused on established metastatic (stage IV) breast cancer is eligible; prevention/diagnosis projects are not considered unless involving novel diagnostics for metastasis.